Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53

Circulation Research

Volumn 115, Issue 9, 2014, Pages 781-789

  Sayin, Volkan I ^a   Khan, Omar M ^a   Pehlivanoglu, Lara E ^a   Staffas, Anna ^a   Ibrahim, Mohamed X ^a   Asplund, Annika ^a   Ågren, Pia ^a   Nilton, Anna ^a   Bergström, Göran ^a   Bergo, Martin O ^a   Borén, Jan ^a   Lindahl, Per ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Atherosclerosis; Cell proliferation; Genes; Macrophages; Mice; Mouse; p53; Transgenic; Zfp148 protein

Indexed keywords

APOLIPOPROTEIN E; PROTEIN P53; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 148; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR; ZFP148 PROTEIN, MOUSE; ZNF148 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; EFFECTOR CELL; GENE DOSAGE; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN TISSUE; LIPID DIET; LIPID METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN PHOSPHORYLATION; ANIMAL; AORTIC DISEASES; ATHEROSCLEROTIC PLAQUE; C57BL MOUSE; CAROTID ARTERY DISEASE; CELL CULTURE; CELL CYCLE CHECKPOINT; DEFICIENCY; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TRANSCRIPTION INITIATION;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CAROTID ARTERY DISEASES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELLS, CULTURED; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HUMANS; MACROPHAGES, PERITONEAL; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921945356     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.304992     Document Type: Article

References (52)

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
2. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491-1493.
3. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488-1491.
4. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678
5. Kuo CL, Murphy AJ, Sayers S, Li R, Yvan-Charvet L, Davis JZ, Krishnamurthy J, Liu Y, Puig O, Sharpless NE, Tall AR, Welch CL. Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation. Arterioscler Thromb Vasc Biol. 2011;31:2483-2492.
6. González-Navarro H, Abu Nabah YN, Vinué A, Andrés-Manzano MJ, Collado M, Serrano M, Andrés V. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol. 2010;55:2258-2268.
7. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5:335-339.
8. Mercer J, Figg N, Stoneman V, Braganza D, Bennett MR. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res. 2005;96:667-674.
9. van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, Vierboom MP, van Eck M, van De Water B, van Berkel TJ, Havekes LM. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE∗3-Leiden transgenic mice. Circ Res. 2001;88:780-786.
10. Merched AJ, Williams E, Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol. 2003;23:1608-1614.
11. Merchant JL, Iyer GR, Taylor BR, Kitchen JR, Mortensen ER, Wang Z, Flintoft RJ, Michel JB, Bassel-Duby R. ZBP-89, a Krüppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol Cell Biol. 1996;16:6644-6653.
12. Wang Y, Kobori JA, Hood L. The ht beta gene encodes a novel CACCC box-binding protein that regulates T-cell receptor gene expression. Mol Cell Biol. 1993;13:5691-5701.
13. Hasegawa T, Takeuchi A, Miyaishi O, Isobe Ki, de Crombrugghe B. Cloning and characterization of a transcription factor that binds to the proximal promoters of the two mouse type I collagen genes. J Biol Chem. 1997;272:4915-4923.
14. Passantino R, Antona V, Barbieri G, Rubino P, Melchionna R, Cossu G, Feo S, Giallongo A. Negative regulation of beta enolase gene transcription in embryonic muscle is dependent upon a zinc finger factor that binds to the G-rich box within the muscle-specific enhancer. J Biol Chem. 1998;273:484-494.
15. Bai L, Merchant JL. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J Biol Chem. 2000;275:30725-30733.
16. Bai L, Kao JY, Law DJ, Merchant JL. Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection. Gastroenterology. 2006;131:841-852.
17. Wu Y, Zhang X, Salmon M, Zehner ZE. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells. 2007;12:905-918.
18. Feng Y, Wang X, Xu L, Pan H, Zhu S, Liang Q, Huang B, Lu J. The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence. FEBS J. 2009;276:4197-4206.
19. Bai L, Merchant JL. ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol. 2001;21:4670-4683.
20. Sayin VI, Nilton A, Ibrahim MX, Ågren P, Larsson E, Petit MM, Hultén LM, Ståhlman M, Johansson BR, Bergo MO, Lindahl P. Zfp148 deficiency causes lung maturation defects and lethality in newborn mice that are rescued by deletion of p53 or antioxidant treatment. PLoS One. 2013;8:e55720.
21. Gustafsson M, Levin M, Skålén K, Perman J, Fridén V, Jirholt P, Olofsson SO, Fazio S, Linton MF, Semenkovich CF, Olivecrona G, Borén J. Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase. Circ Res. 2007;101:777-783.
22. Nicoletti A, Kaveri S, Caligiuri G, Bariéty J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998;102:910-918.
23. Khan OM, Akula MK, Skålen K, Karlsson C, Ståhlman M, Young SG, Borén J, Bergo MO. Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice. Circulation. 2013;127:782-790.
24. Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19:1166-1172.
25. Butcher MJ, Herre M, Ley K, Galkina E. Flow cytometry analysis of immune cells within murine aortas. Journal of visualized experiments: JoVE. 2011
26. Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genové G, Arrondel C, Gerwins P, Kurschat C, Schermer B, Benzing T, Harvey SJ, Kreuger J, Lindahl P. Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1. Genome Med. 2009;1:108.
27. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 1976;15:212-216.
28. Andersson L, Boström P, Ericson J, Rutberg M, Magnusson B, Marchesan D, Ruiz M, Asp L, Huang P, Frohman MA, Borén J, Olofsson SO. PLD1 and ERK2 regulate cytosolic lipid droplet formation. J Cell Sci. 2006;119:2246-2257.
29. Levin MC, Jirholt P, Wramstedt A, Johansson ME, Lundberg AM, Trajkovska MG, Ståhlman M, Fogelstrand P, Brisslert M, Fogelstrand L, Yan ZQ, Hansson GK, Björkbacka H, Olofsson SO, Borén J. Rip2 deficiency leads to increased atherosclerosis despite decreased inflammation. Circ Res. 2011;109:1210-1218.
30. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014;6:221ra15.
31. Fagerberg B, Ryndel M, Kjelldahl J, Akyürek LM, Rosengren L, Karlström L, Bergström G, Olson FJ. Differences in lesion severity and cellular composition between in vivo assessed upstream and downstream sides of human symptomatic carotid atherosclerotic plaques. J Vasc Res 2010;47:221-230.
32. Li X, Xiong JW, Shelley CS, Park H, Arnaout MA. The transcription factor ZBP-89 controls generation of the hematopoietic lineage in zebrafish and mouse embryonic stem cells. Development. 2006;133:3641-3650.
33. Ohneda K, Ohmori S, Ishijima Y, Nakano M, Yamamoto M. Characterization of a functional ZBP-89 binding site that mediates Gata1 gene expression during hematopoietic development. J Biol Chem. 2009;284:30187-30199.
34. Woo AJ, Kim J, Xu J, Huang H, Cantor AB. Role of ZBP-89 in human globin gene regulation and erythroid differentiation. Blood. 2011;118:3684-3693.
35. Li X, Romain RD, Park D, Scadden DT, Merchant JL, Arnaout MA. Stress hematopoiesis is regulated by the Krüppel-like transcription factor ZBP-89. Stem Cells. 2014;32:791-801.
36. Nilton A, Sayin VI, Staffas A, Larsson E, Rolf J, Petit MM, Palmqvist L, Swolin B, Cardell S, Lindahl P. Zinc finger protein 148 is dispensable for primitive and definitive hematopoiesis in mice. PLoS One. 2013;8:e70022.
37. Boesten LS, Zadelaar AS, van Nieuwkoop A, Hu L, Teunisse AF, Jochemsen AG, Evers B, van de Water B, Gijbels MJ, van Vlijmen BJ, Havekes LM, de Winther MP. Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice. Atherosclerosis. 2009;207:399-404.
38. Helming L. Inflammation: cell recruitment versus local proliferation. Curr Biol. 2011;21:R548-R550.
39. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. 2011;332:1284-1288.
40. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci U S A. 1990;87:4600-4604.
41. Rekhter MD, Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am J Pathol. 1995;147:668-677.
42. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest. 1993;91:1469-1480.
43. Manolakou P, Angelopoulou R, Bakoyiannis C, Psathas E, Bastounis E, Kavantzas N, Patsouris E. Cellular proliferation in complicated versus uncomplicated atherosclerotic lesions: total cell population, foam cells and newly formed microvessels. Tissue Cell. 2009;41:408-413.
44. Andrés V, Pello OM, Silvestre-Roig C. Macrophage proliferation and apoptosis in atherosclerosis. Curr Opin Lipidol. 2012;23:429-438.
45. Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res. 2009;50(suppl):S382-S387.
46. Heo KS, Lee H, Nigro P, Thomas T, Le NT, Chang E, McClain C, Reinhart-King CA, King MR, Berk BC, Fujiwara K, Woo CH, Abe J. PKCζ mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J Cell Biol. 2011;193:867-884.
47. Heo KS, Chang E, Le NT, Cushman H, Yeh ET, Fujiwara K, Abe J. De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res. 2013;112:911-923.
48. Warboys CM, de Luca A, Amini N, et al. Disturbed flow promotes endothelial senescence via a p53-dependent pathway. Arterioscler Thromb Vasc Biol. 2014;34:985-995.
49. Sanz-González SM, Barquín L, García-Cao I, Roque M, González JM, Fuster JJ, Castells MT, Flores JM, Serrano M, Andrés V. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res. 2007;75:803-812.
50. Le Guezennec X, Brichkina A, Huang YF, Kostromina E, Han W, Bulavin DV. Wip1-dependent regulation of autophagy, obesity, and atherosclerosis. Cell Metab. 2012;16:68-80.
51. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378:206-208.
52. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203-206.